As of November 7, 2026, Entera Bio Ltd. is a publicly traded company (Nasdaq: ENTX). The largest holder reporting an active stake on Schedule 13D is Biotechnology Value Fund LP, at 9.99%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D, August 4, 2026).
Is this your company?
About to sign with, pay or invest in Entera Bio Ltd.? See the free Snapshot first.
Free to see. No signup.
Is Entera Bio Ltd. a real, registered company?
- Entera Bio Ltd. files with the SEC under CIK 1638097 (its SEC filings).
- Its shares are listed under the ticker ENTX on Nasdaq (SEC company record).
- Incorporated in L3, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Entera Bio Ltd. in our court records and SEC 8-K records (as of 2026-11-07).
- Leadership changes: the latest reported is Haya Taitel, Director (Form 8-K filed 2026-10-27). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Venrock Healthcare Capital Partners III, L.P. (filed 2026-10-30).
Who are Entera Bio Ltd.'s owners and officers?
Entera Bio Ltd.: industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-10-30).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2026-08-12)
- : Director (Form D, 2026-08-12)
- : Director (Form D, 2026-08-12)
- : Executive Officer (Form D, 2026-08-12)
- : Director (Form D, 2026-08-12)
- : Director (Form D, 2026-08-12)
- : Director (Form D, 2026-08-12)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-30 | Venrock Healthcare Capital Partners Iii, L.P. | 5.1% |
| Schedule 13G, 2026-08-04 | Vivo Opportunity, LLC | 6.9% |
| Schedule 13D, 2026-08-04 | Biotechnology Value Fund L P | 9.99% |
| Schedule 13G, 2026-08-04 | Seven Fleet Capital Management LP | 4.1% |
| Schedule 13G, 2026-08-04 | Tcg Crossover Gp Iii, LLC | 7.1% |
| Schedule 13G, 2026-08-04 | Longitude Capital Partners V, LLC | 4.6% |
| Schedule 13G/A, 2025-11-14 | Point72 Asset Management, L.P. | 2.6% |
Questions about who owns Entera Bio Ltd.
Who owns Entera Bio Ltd.?
On this page, 4 holders' latest ownership filings report 5% or more of Entera Bio Ltd.: Biotechnology Value Fund L P (9.99%, Schedule 13D, filed 2026-08-04), Tcg Crossover Gp Iii, LLC (7.1%, Schedule 13G, filed 2026-08-04), Vivo Opportunity, LLC (6.9%, Schedule 13G, filed 2026-08-04) and Venrock Healthcare Capital Partners Iii, L.P. (5.1%, Schedule 13G, filed 2026-10-30).
Who are the largest shareholders of Entera Bio Ltd.?
By the share each holder's latest filing reports, the largest holders of Entera Bio Ltd. on this page are Biotechnology Value Fund L P (9.99%), Tcg Crossover Gp Iii, LLC (7.1%) and Vivo Opportunity, LLC (6.9%).
When did Biotechnology Value Fund L P buy into Entera Bio Ltd.?
The filings give report dates, not purchase dates. The earliest filing from Biotechnology Value Fund L P on this page is the Schedule 13D, filed 2026-08-04, reporting 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Entera Bio Ltd.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Entera Bio Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Entera Bio Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-27 | Haya Taitel | Director | departed | 2026-12-01 |
| Form 8-K, 2026-10-06 | Laura Hamill | Director | appointed | 2026-12-01 |
| Form 8-K, 2026-10-06 | Yonatan Malca | Director | departed | 2026-12-01 |
Which insiders own Entera Bio Ltd. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Knoll Capital Management, LLC, a 10% owner: 5,534,275 shares (3.2% of shares outstanding) (Form 3, 2024-11-20).
- , the chief executive and a director: 847,135 shares (0.49% of shares outstanding) (Form 4, 2026-07-16).
- , a director: 344,654 shares (0.20% of shares outstanding), 338,454 held directly and 6,200 indirectly (Form 4, 2026-01-02).
- , a director: 208,132 shares (0.12% of shares outstanding) (Form 4, 2026-08-07).
- , the chief of r and d: 189,033 shares (0.11% of shares outstanding) (Form 4, 2026-05-08).
Shares outstanding: 174,137,771 as of 2026-11-02, from the company's latest SEC cover page.
How much has Entera Bio Ltd. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-08-12 | $275M | $275M |
| Form D, 2024-01-02 | $6.61M | $6.61M |
Keep reading
More on Entera Bio Ltd. and the records around it.
Entera Bio Ltd. elsewhere on the record
- 5%+ stake filings Oct 2026
- Company profile and every filing Aug 2026
- Form D filing Aug 2026
- Leadership changes Jul 2026
Companies that share a holder
- Longitude Capital Partners V, LLC also filed stake reports on 3 other companies: CytomX Therapeutics, Inc. (May 2026), Mobia Medical, Inc. (May 2026), Veradermics, Incorporated (May 2026)
- Seven Fleet Horizon Master Fund LP also filed stake reports on 3 other companies: CytomX Therapeutics, Inc. (May 2026), Veradermics, Inc (May 2026), CG Oncology, Inc. (Oct 2025)
- TCG Crossover GP III, LLC also filed stake reports on 3 other companies: Research Alliance Corporation III (Aug 2026), Editas Medicine, Inc. (Jun 2026), InflaRx N.V. (May 2026)
Related pages
Funding and filing history5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/entera-bio-ltd